The MIMESIS team is proud to be part of PREMYOM (Prise en charge et Ralentissement de l’Epidémie de MYopie par l’Optique Médicale), a major collaborative project aiming to develop medical optics solutions to manage and slow the global myopia epidemic.
The project officially kicked off in July 2024 in Paris, hosted by project coordinator EssilorLuxottica at its Centre for Innovation and Technologies.
A growing public health challenge
Myopia is a rapidly growing threat to public health. By 2050, approximately 4.7 billion people — over 50% of the world’s population — are expected to be myopic, up from 2.8 billion today. Among them, up to one billion will have high myopia (above -5 diopters), significantly increasing the risk of serious eye conditions such as glaucoma and retinal detachment.
Towards personalized myopia management
Current myopia control solutions are not personalized and lack a deep understanding of the individual mechanisms driving myopia progression. PREMYOM aims to change this by investigating the clinical and biological factors of myopia progression and developing innovative ophthalmic solutions tailored to each patient’s needs.
A multidisciplinary consortium
PREMYOM brings together a unique combination of expertise from industry, healthcare and research: EssilorLuxottica (coordinator), Hôpital Fondation Adolphe de Rothschild, Institut Français de Myopie, Inria, InSimo, Institut Mines-Télécom, and Institut de la Vision. The project runs from 2024 to 2029 and is co-funded by the French government as part of the France 2030 plan.
Learn more: premyom.com
This project is funded as part of the France 2030 plan.
